Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Recurrent Malignant Pleural Mesothelioma
NCT02568449Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in malignant pleural mesothelioma (MPM), sponsored by Barbara Ann Karmanos Cancer Institute. Started Mar 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02568449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568449.